An Inside Look at the Role of Data Monitoring Committees with Dr. Jonathan Seltzer - a podcast by WIRB-Copernicus Group

In this episode, WCG’s President of Patient Advocacy, Steve Smith, interviews Dr. Jonathan Seltzer, MD, Chief Scientific Officer at WCG, expert on data safety monitoring boards, biomarkers, biostatistics, and clinical endpoints. During their conversation, Steve and Dr. Seltzer discuss how biomarkers are appropriate for the use of trials, especially when clinical data is tough to get. Part of this discussion turns to Duchenne’s Muscular Dystrophy (an inherited rare muscular disease) on how Patient Advocacy Groups are working with the FDA to define risk vs. benefit, and how promising a biomarker for this condition - as well as many other rare disorders - would be.

Further episodes of WCG Talks Trials

Further podcasts by WIRB-Copernicus Group

Website of WIRB-Copernicus Group